Prima, a potentially breakthrough wireless bionic vision system (BVS) that generates electrical impulses at the retinal level, continues to advance through the PRIMAvera pivotal EU study. Prima aims to restore a form of central visual perception in patients with advanced dry age-related macular degeneration (dry-AMD) involving geographic atrophy (GA). While we have pushed back our potential launch forecast to H124 (from H223), after tweaking our market growth assumptions, we now obtain a higher equity valuation of €143.3m (versus €138.0m previously).
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.